

Rapid antigen test	Quarantine required		Serial testing required	
	Exit test ^a	Entry and exit test ^a	Frequency ^b	Prob. of a false positive ^c
BD Veritor ^{d,e}	9 (8–9)	9 (8–9)	2 (2–2)	0.0389 (0.00847–0.155)
BinaxNOW ^{e,f}	9 (8–9)	9 (8–9)	2 (2–2)	0.104 (0.0415–0.217)
BinaxNOW ^{g,f}	9 (8–9)	8 (8–9)	2 (2–3)	0.0474 (0.0255–0.0751)
BinaxNOW ^{h,f}	9 (8–9)	9 (8–9)	2 (2–2)	0.0558 (0.0357–0.0841)
CareStart ^{e,f}	9 (8–9)	9 (8–9)	2 (2–2)	0.00675 (0.00408–0.333)
CareStart ^{e,i}	8 (8–9)	8 (8–9)	3 (2–3)	0.0355 (0.00729–0.192)
CareStart ^{f,g}	9 (8–9)	9 (8–9)	2 (2–2)	0.117 (0.0752–0.173)
CareStart ^{f,h}	9 (8–9)	9 (8–9)	2 (2–2)	0.112 (0.0729–0.166)
Celltrion DiaTrust ^{e,i}	8 (8–9)	8 (8–9)	2 (2–3)	0.0723 (0.009–0.267)
Clip COVID ^{e,f}	8 (8–9)	8 (8–9)	2 (2–3)	0.00675 (0.00331–0.145)
Ellume ^{e,j}	8 (8–9)	8 (8–9)	3 (2–3)	0.141 (0.0642–0.363)
Liaison ^{e,f}	8 (8–9)	8 (8–9)	2 (2–3)	0.00675 (0.00314–0.174)
Liaison ^{e,i}	8 (8–9)	8 (8–9)	2 (2–3)	0.0575 (0.00868–0.222)
LumiraDx ^{e,f}	8 (8–9)	8 (8–9)	3 (2–3)	0.155 (0.0796–0.381)
LumiraDX ^{e,i}	8 (8–9)	8 (8–9)	3 (2–3)	0.108 (0.0489–0.287)
Omnia ^{e,f}	9 (8–9)	9 (8–9)	2 (2–2)	0.00675 (0.00444–0.481)
SCoV-2 Ag Detect ^{e,f}	9 (8–9)	9 (8–9)	2 (2–2)	0.00675 (0.00389–0.0871)
Simoa ^{e,i}	8 (8–9)	8 (8–9)	2 (2–3)	0.00675 (0.00337–0.398)
Sofia ^{e,f}	8 (8–9)	8 (8–9)	2 (2–3)	0.00675 (0.00323–0.113)
Sofia ^{g,f}	9 (8–9)	9 (8–9)	2 (1–2)	0.109 (0.0658–0.261)
Sofia ^{h,f}	9 (8–9)	9 (8–9)	2 (2–2)	0.0944 (0.0576–0.147)
Sofia 2 Flu+SARS ^{e,f}	8 (8–9)	8 (8–9)	2 (2–3)	0.00675 (0.00314–0.155)
Status COVID-19/Flu ^{e,i}	9 (8–9)	9 (8–9)	2 (2–3)	0.00675 (0.00362–0.243)
Vitros ^{e,i}	9 (8–9)	9 (8–9)	2 (1–2)	0.00675 (0.00406–0.308)

^a Quarantine durations that are equivalent or better than a 7-day quarantine with an RT-PCR test conducted 24 h before exit.

^b The minimum required testing frequency for serial testing such that the effective reproductive number is less than one.

^c The probability of at least one false positive in a two-week period of serial testing under the minimum required testing frequency.

^d Peer-reviewed

^e Data from EUA submission

^f Anterior nasal swab

^g Data from community testing

^h Combined data from EUA submission and community testing

ⁱ Nasopharyngeal swab

^j Mid-turbinate swab